An Overview of Systematic Reviews of Shenmai Injection for Healthcare

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2014 Mar 27

PMID 24669229

Citations 23

Authors

Ling-Yan Lu

Guo-Qing Zheng

Yan Wang

Affiliations

Soon will be listed here.

Abstract

Shenmai injection (SMI) is widely applied in clinical practice as an organ protector. This overview is to evaluate the current evidence from systematic reviews (SRs) of SMI for healthcare. The literature searches were carried out in 6 databases without language restrictions until December 2012. The quality of the primary studies from the respective SRs was evaluated by using Jadad score. The overview quality assessment questionnaire (OQAQ) was used to evaluate the methodological quality of all included SRs. Twenty eligible SRs were identified. They reported a wide range of conditions, including SMI for cardio/cerebrovascular diseases, viral myocarditis, tumor chemotherapy, and adverse drug reactions. Most of the primary studies were of good quality only in 1 SR of non-small-cell lung cancer. According to the OQAQ scores, the quality of included SRs was variable and six reviews were of high quality with a score of 5 points. Two SRs showed that SMI had low adverse drug reaction occurrence. In conclusion, there is mixed evidence to support efficacy of SMI for an adjunct therapy to tumor chemotherapy and premature evidence for the use of SMI for cardio/cerebrovascular disorders and viral myocarditis. SMI seems generally safe for clinical application. Further large sample-size and well-designed RCTs are needed.

Citing Articles

Investigation of Ginseng-Ophiopogon Injection on Enhancing Physical Function by Pharmacogenomics and Metabolomics Evaluation.

Meimei C, Jingru Z, Huijuan G, Candong L Comb Chem High Throughput Screen. 2023; 27(19):2838-2849.

PMID: 37957852 DOI: 10.2174/0113862073244102231020050502.

Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer.

Yu D, Yang P, Lu X, Huang S, Liu L, Fan X Cell Commun Signal. 2023; 21(1):169.

PMID: 37430270 PMC: 10332015. DOI: 10.1186/s12964-023-01184-3.

Quality monitoring of Shenmai injection by HPLC pharmacodynamic fingerprinting.

Yang G, Li S, Sun X, Lv Y, Huang H BMC Chem. 2023; 17(1):28.

PMID: 36966333 PMC: 10039686. DOI: 10.1186/s13065-023-00920-7.

Anti-Inflammatory Effects and Molecular Mechanisms of Shenmai Injection in Treating Acute Pancreatitis: Network Pharmacology Analysis and Experimental Verification.

He Y, Hu C, Liu S, Xu M, Liang G, Du D Drug Des Devel Ther. 2022; 16:2479-2495.

PMID: 35941928 PMC: 9356589. DOI: 10.2147/DDDT.S364352.

Shenmai injection enhances cisplatin-induced apoptosis through regulation of Mfn2-dependent mitochondrial dynamics in lung adenocarcinoma A549/DDP cells.

Chen Y, Sun Y, Zhao Q, Liu C, Wang C Cancer Drug Resist. 2022; 4(4):1047-1060.

PMID: 35582383 PMC: 8992451. DOI: 10.20517/cdr.2021.94.

References

Li J, Wang H, Li S, Yu X, Wang Z . Shenmai injection for chronic pulmonary heart disease: a systematic review and meta-analysis. J Altern Complement Med. 2011; 17(7):579-87. DOI: 10.1089/acm.2010.0354. View

Kotsirilos V . Complementary and alternative medicine. Part 2--evidence and implications for GPs. Aust Fam Physician. 2005; 34(8):689-91. View

Xia C, Wang G, Sun J, Hao H, Xiong Y, Gu S . Simultaneous determination of ginsenoside Rg1, Re, Rd, Rb1 and ophiopogonin D in rat plasma by liquid chromatography/electrospray ionization mass spectrometric method and its application to pharmacokinetic study of 'SHENMAI' injection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 862(1-2):72-8. DOI: 10.1016/j.jchromb.2007.11.020. View

Wang L, Wang W, Zhao X, Jin L, Bai Y, Yao H . Effect of Shenmai injection, a traditional Chinese medicine, on pulmonary dysfunction after tourniquet-induced limb ischemia-reperfusion. J Trauma. 2011; 71(4):893-7. DOI: 10.1097/TA.0b013e318205e279. View

Wang L, Yuan Q, Marshall G, Cui X, Cheng L, Li Y . Adverse drug reactions and adverse events of 33 varieties of traditional Chinese medicine injections on National Essential medicines List (2004 edition) of China: an overview on published literatures. J Evid Based Med. 2011; 3(2):95-104. DOI: 10.1111/j.1756-5391.2010.01073.x. View

Flower A, Witt C, Liu J, Ulrich-Merzenich G, Yu H, Lewith G . Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol. 2012; 140(3):550-4. DOI: 10.1016/j.jep.2011.12.017. View

Oxman A, Guyatt G . Validation of an index of the quality of review articles. J Clin Epidemiol. 1991; 44(11):1271-8. DOI: 10.1016/0895-4356(91)90160-b. View

Lee M, Ernst E . Systematic reviews of t'ai chi: an overview. Br J Sports Med. 2011; 46(10):713-8. DOI: 10.1136/bjsm.2010.080622. View

Shauer A, Gotsman I, Keren A, Zwas D, Hellman Y, Durst R . Acute viral myocarditis: current concepts in diagnosis and treatment. Isr Med Assoc J. 2013; 15(3):180-5. View

10.

Al Faleh K, Al-Omran M . Reporting and methodologic quality of Cochrane Neonatal review group systematic reviews. BMC Pediatr. 2009; 9:38. PMC: 2709610. DOI: 10.1186/1471-2431-9-38. View

11.

Bai Y, Yao H, Hu M, Wang L, Jin L, Wang W . Effects of shenmai injection on pulmonary aquaporin 1 in rats following traumatic brain injury. Chin Med J (Engl). 2011; 124(3):457-60. View

12.

Xia C, Sun J, Wang G, Shang L, Zhang X, Zhang R . Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. Planta Med. 2009; 76(3):245-50. DOI: 10.1055/s-0029-1186082. View

13.

Li F, Shen Y . [Meta-analysis on efficacy and safety of Shenmai injection in treatment of coronary heart disease]. Zhongguo Zhong Yao Za Zhi. 2013; 37(23):3651-8. View

14.

Ernst E, Lee M, Choi T . Acupuncture for insomnia? An overview of systematic reviews. Eur J Gen Pract. 2011; 17(2):116-23. DOI: 10.3109/13814788.2011.568475. View

15.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

16.

Zhang L, Hu J, Xiao L, Zhang Y, Zhao W, Zheng W . Adverse drug reactions of Shenmai injection: a systematic review. J Evid Based Med. 2011; 3(3):177-82. DOI: 10.1111/j.1756-5391.2010.01089.x. View

17.

Schulz K, Altman D, Moher D . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340:c332. PMC: 2844940. DOI: 10.1136/bmj.c332. View

18.

Vickers A, Goyal N, Harland R, Rees R . Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials. 1998; 19(2):159-66. DOI: 10.1016/s0197-2456(97)00150-5. View

19.

Liu Z, Liu Z, Liu J, Kwong J . Herbal medicines for viral myocarditis. Cochrane Database Syst Rev. 2013; (8):CD003711. DOI: 10.1002/14651858.CD003711.pub5. View

20.

Hu J, Zhang W, Xie Y, Wang L, Nie X, Zhang Y . [Meta-analysis of Shenmai injection treatment for acute myocardial infarction]. Zhongguo Zhong Yao Za Zhi. 2013; 37(18):2760-7. View